REGENXBIO Charts Accelerated Path for Duchenne Treatment. REGENXBIO announced significant progress for its gene therapy candidate RGX-202 designed to treat Duchenne muscular dystrophy, a severe genetic disorder affecting muscle function. The company revealed that its pivotal Phase III clinical trial has successfully met its primary endpoint, demonstrating the therapy's efficacy in patients with this debilitating condition. The safety profile appears manageable, with serious adverse events remaining within acceptable parameters for a gene therapy approach. Based on these positive results, REGENXBIO is targeting an accelerated approval pathway with the FDA, potentially bringing RGX-202 to market as early as 2027. This timeline represents a significant achievement in the competitive landscape of rare genetic disease treatments.
Post from MarketNews_en
Log in to interact with content.